Fig. 1 · Structure

Documents & Downloads

Ubenimex (Bestatin)

Cat. No. A10958 CAS 58970-76-6

reversible Protease inhibitor

Ubenimex, also known as NK 421 and Bestatin, is a CD13 inhibitor. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism. Ubenimex synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma. Ubenimex inhibits cell proliferation, migration and invasion by inhibiting the expression of APN and inducing autophagic cell death in prostate cancer cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 500 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 30737134]
A549 IC50 > 500 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 29859750]
A549 IC50 > 500 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 29202398]
A549 IC50 > 500 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 27670098]
A549 IC50 > 500 μM Antiproliferative activity against human A549 cells after 48 hrs by MTT assay [PMID: 27322756]
A549 IC50 15.93 μM Antiproliferative activity against human A549 cells in presence of 5-FU after 48 hrs by MTT assay [PMID: 29202398]
A549 IC50 512.9 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay [PMID: 22901392]
AGS IC50 > 200 μM Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 34917257]
B16-BL6 GI50 > 500 μM Cytotoxicity against mouse B16-BL6 cells assessed as cell growth inhibition after 24 hrs by MTT assay [PMID: 24900417]
ES-2 IC50 > 500 μM Cytotoxicity against human ES2 cells assessed as inhibition of cell growth by MTT assay [PMID: 32791404]
HCT-116 IC50 > 1000 μM Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay [PMID: 22901392]
HCT-116 IC50 > 500 μM Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay [PMID: 29859750]
HCT-116 IC50 315.25 μM Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay [PMID: 27322756]
HCT-116 IC50 357.61 μM Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay [PMID: 29202398]
HCT-116 IC50 42.54 μM Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by WST1 assay [PMID: 28065501]
HCT-116 IC50 44.06 μM Antiproliferative activity against human HCT116 cells in presence of 5-FU after 48 hrs by MTT assay [PMID: 29202398]
HEL IC50 > 500 μM Antiproliferative activity against human HEL cells after 48 hrs by MTT assay [PMID: 27670098]
HEL IC50 416.65 μM Antiproliferative activity against human HEL cells after 48 hrs by MTT assay [PMID: 27322756]
HeLa IC50 > 100 μM Inhibition of HDAC1/HDAC2 in human HeLa cells nuclear extract preincubated for 5 mins before Boc-Lys (acetyl)-AMC substrate addition for 30 mins by microplate reader analysis [PMID: 26629857]
HeLa IC50 > 500 μM Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay [PMID: 27670098]

20 records · Scroll to view more

Ubenimex (Bestatin) Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Ubenimex (Bestatin) from 3 published references. In vitro models include MDCK cells cultured atop a type I collagen matrix.

Ubenimex (Bestatin) In Vitro Studies

Ubenimex was added to both the upper and lower wells of MDCK cells cultured atop a type I collagen matrix. At 10 μM, invasion was unaffected compared with SF/HGF-stimulated control cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Unchanged invasion in stimulated MDCK cells

Cell-based study · MDCK cells cultured atop a type I collagen matrix [1]

In MDCK cells cultured atop a type I collagen matrix, Ubenimex added to both the upper and lower wells left invasion unaffected compared with SF/HGF-stimulated control cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean number of invasive foci ± 1 SDReported result MDCK invasion by SF/HGF-stimulated cells was unaffected[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
12-d culture period
Method
added to both the upper and lower wells
Co-treatment
Other interventions in this design: SF/HGF 50 ng/ml. Compound effect isolated by the comparison: SF/HGF-stimulated cells.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ubenimex; Compound label in the paper: Bestatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Invasion and Tubulogenesis Assays > Collagen. (S30); Figure 1 legend (S128, S132, S133, S135)

mean number of invasive foci ± 1 SD: mean number of invasive foci ± 1 SD; comparator: SF/HGF-stimulated cells — Figure 1 legend (S133, S135)

Ubenimex (Bestatin) In Vivo Studies

Ubenimex administered by daily oral gavage significantly decreased polyp formation in C57BL/6J-ApcMin/+ mice compared with untreated controls. In 615 mice bearing MFC-LAP3-overexpressing tumors, Ubenimex alone at 5 mg/kg reduced tumor volume by 37.5% compared with the DMSO + PBS control. [2,3]

Ubenimex reduces polyp formation in mice

Animal study · C57BL/6J-ApcMin/+ mice; n = 6 [2]

C57BL/6J-ApcMin/+ mice received Ubenimex at 5 or 15 mg/kg by daily oral gavage for 8 weeks. Polyp formation decreased significantly compared with the untreated control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Polyp numberReported result Bestatin (5 or 15 mg/kg) daily for 8 weeks: a significant (p < .001) decrease in polyp formation in mice treated with bestatin compared with the control group.[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily for 8 weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ubenimex 5 or 15 mg/kguntreated control groupBestatin (5 or 15 mg/kg) daily for 8 weeks: a significant (p < .001) decrease in polyp formation in mice treated with bestatin compared with the control group.[2]
Ubenimex 5 or 15 mg/kg
Model: C57BL/6J-ApcMin/+ mice; n = 6
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ubenimex; Compound label in the paper: Bestatin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Patients and methods > Mouse model and drug administration (S35, S38); Results > Bestatin reduces intestinal adenoma formation in ApcMin/+ mice (S119, S121); Fig. 6 legend (S186, S187, S188)

Polyp number: Polyp number; comparator: untreated control group — Patients and methods > Mouse model and drug administration (S38); Fig. 6 legend (S186, S187)

Ubenimex 5 or 15 mg/kg · Patients and methods > Mouse model and drug administration (S38); Results > Bestatin reduces intestinal adenoma formation in ApcMin/+ mice (S121); Fig. 6 legend (S187)

Ubenimex reduces tumor volume in mice bearing MFC tumors

Animal study · 615 mice bearing MFC-LAP3-overexpressing tumors; n = 3 per group [3]

Ubenimex (5 mg/kg) was given daily via oral gavage. Ubenimex alone reduced tumor volume by 37.5%. Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumetumor volume Ubenimex alone (5 mg/kg): 37.5%; (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume[3]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily; 16-day treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ubenimex 5 mg/kgDMSO + PBS (control); Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volumeUbenimex (5 mg/kg) was given daily via oral gavage. Ubenimex alone reduced tumor volume by 37.5%. Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume.[3]
Ubenimex 5 mg/kg
Model: 615 mice bearing MFC-LAP3-overexpressing tumors; n = 3 per group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ubenimex

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Mouse models (S84); Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S103, S104, S105, S106, S107, S111)

tumor volume: tumor volume; comparator: DMSO + PBS (control); Tumor growth inhibition ratio, calculated as (V0−Ve)/V[0], where V[0] = baseline volume and Ve = endpoint volume — Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S105, S107, S111)

Ubenimex 5 mg/kg · Methods > Mouse models (S84); Results > Ubenimex sensitizes anti PD-L1 blockade in syngeneic mouse GC models (S105, S107, S111)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 58970-76-6
Applications reversible Protease inhibitor
Formula C16H24N2O4
Molecular Weight 308.378
Synonyms NK 421; Bestatin; NSC 265489
SMILES
CC(C)C[C@@H](C(O)=O)NC([C@@H](O)[C@H](N)CC1=CC=CC=C1)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 0.35 mg/mL (1.13 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ubenimex (Bestatin) Research References

  1. [1] Hotary K, Allen E, Punturieri A, et al. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol (2000). PMID: 10851027 DOI: 10.1083/jcb.149.6.1309 Source material
  2. [2] Zhao S, Yao K, Li D, et al. Inhibition of LTA4H by bestatin in human and mouse colorectal cancer. EBioMedicine (2019). PMID: 31085102 DOI: 10.1016/j.ebiom.2019.05.008 Source material
  3. [3] Zhao C, Li J, Zheng J, et al. Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A. Cell Death Dis (2026). PMID: 41748538 DOI: 10.1038/s41419-026-08509-3 Source material

Added to your cart

View Cart Checkout
Loading...